Dr. David R. Sutton JR., M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- Wake Forest University School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 613
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: Wake Forest University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
FL license ME58349 -
Internal Medicine Physician
FL license ME58349 -
Specialist
FL license ME58349
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Medical Center - Jacksonville Jacksonville, FL
- Baptist Medical Center Beaches Jacksonville Beach, FL
- Ascension St Vincent's Riverside Jacksonville, FL
- Baptist Medical Center - Nassau Fernandina Beach, FL
- Ed Fraser Memorial Hospital Macclenny, FL
Medical groups
- Northeast Florida Endocrine and Diabetes Associates PA (80 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 613
- Services billed
- 2,592
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,374 | 596 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 397 | 148 |
| Ultrasound scan of head and neck soft tissue | 223 | 181 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | 35 | 30 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 25 | 13 |
| Established patient office or other outpatient visit, 20-29 minutes | 20 | 19 |
| Dxa bone density measurement of hip, pelvis, spine | 18 | 18 |
| New patient office or other outpatient visit, 45-59 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Jacksonville, FL | 542 |
| Jardiance (empagliflozin) Other prescribers in Jacksonville, FL | 419 |
| Mounjaro (tirzepatide) Other prescribers in Jacksonville, FL | 412 |
| Ozempic (semaglutide) Other prescribers in Jacksonville, FL | 406 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Jacksonville, FL | 349 |
| Synthroid (levothyroxine sodium) Other prescribers in Jacksonville, FL | 335 |
| Pioglitazone Hcl Other prescribers in Jacksonville, FL | 287 |
| Rosuvastatin Calcium Other prescribers in Jacksonville, FL | 256 |
| Tresiba Flextouch U-200 (insulin degludec) Other prescribers in Jacksonville, FL | 227 |
| Metformin Hcl Other prescribers in Jacksonville, FL | 164 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 26 companies reported 288 payments worth $63,038 in total to this clinician.
| Lilly USA, LLC | $39,557 |
|---|---|
| Novo Nordisk Inc | $14,374 |
| AbbVie Inc. | $3,164 |
| Abbott Laboratories | $2,726 |
| Insulet Corporation | $539 |
| Corcept Therapeutics | $507 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $346 |
| Ascendis Pharma Endocrinology Inc | $245 |
| Compensation for services other than consulting (speaking, faculty) | $54,275 |
|---|---|
| Food and Beverage | $5,252 |
| Speaking at a medical education program | $1,800 |
| Travel and Lodging | $1,711 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $5,406 |
| Lilly USA, LLC Feb 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,600 |
| Novo Nordisk Inc Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $3,023 |
| Novo Nordisk Inc Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,093 |
| Lilly USA, LLC Aug 5, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Sep 26, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| AbbVie Inc. Sep 8, 2025 | Compensation for services other than consulting (speaking, faculty) SYNTHROID · IMMUNOLOGY | $1,575 |
| AbbVie Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,575 |
All 54 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $675 |
| Lilly USA, LLC Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| AbbVie Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,575 |
| Novo Nordisk Inc Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $494 |
| Lilly USA, LLC Sep 26, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Sep 26, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $675 |
| Lilly USA, LLC Sep 19, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $675 |
| AbbVie Inc. Sep 8, 2025 | Compensation for services other than consulting (speaking, faculty) SYNTHROID · IMMUNOLOGY | $1,575 |
| Lilly USA, LLC Sep 3, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Aug 28, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Aug 28, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Aug 26, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO; ZEPBOUND · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $450 |
| Lilly USA, LLC Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Aug 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Aug 5, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Aug 5, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $675 |
| Novo Nordisk Inc Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,093 |
| Lilly USA, LLC Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Abbott Laboratories Jul 16, 2025 | Speaking at a medical education program FREESTYLE LIBRE 3 · Diabetes Care | $1,000 |
| Abbott Laboratories Jul 16, 2025 | Speaking at a medical education program FREESTYLE LIBRE 3 · Diabetes Care | $800 |
| Lilly USA, LLC Jul 15, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Jul 11, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Jun 27, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Novo Nordisk Inc Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $930 |
| Novo Nordisk Inc Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $3,023 |
| Novo Nordisk Inc Jun 3, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $930 |
| Lilly USA, LLC May 27, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $450 |
| Lilly USA, LLC May 9, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO; ZEPBOUND · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,575 |
| Lilly USA, LLC May 6, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Apr 28, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Mar 31, 2025 | Travel and Lodging MOUNJARO · Diabetes · travel to JACKSONVILLE, FL | $16.80 |
| Lilly USA, LLC Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $675 |
| Lilly USA, LLC Mar 12, 2025 | Travel and Lodging MOUNJARO · Diabetes · travel to ATLANTA, GA | $190 |
| Lilly USA, LLC Mar 12, 2025 | Travel and Lodging MOUNJARO · Diabetes · travel to ATLANTA, GA | $48.00 |
| Lilly USA, LLC Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Novo Nordisk Inc Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $5,406 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $399 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $225 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $57.51 |
| Lilly USA, LLC Feb 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,600 |
| Lilly USA, LLC Feb 6, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $774 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 7 companies. The companies reported $317,407 in research payments for these studies, mostly to the institutions running them.
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - A master protocol to investigate the efficacy and safety of orforglipron once daily in participants with hypertension and obesity or overweight: randomized, double-blind, placebo-controlled trials (attain-hypertension…
Eli Lilly and Company - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Dis…
Novartis Pharmaceuticals Corporation - Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Alnylam Pharmaceuticals Inc. - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharma GmbH & Co.kg - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals Corporation - CIP341 IMPACT2
Medtronic, Inc. - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim International GmbH - A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)
Alnylam Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.